Grant: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Sussex Research Laboratories Inc
$101,635.00
Synthesis and testing of glycan scaffolds (mono- and multi-valent forms) for evaluating glycan receptors of SARS-CoV-2
FY 2021-22 · 2021-05-10
Summary
For pathogens such as the SARS-CoV-2 virus that are spread through inhalation, the cells of the lung are the first line of defense for the host. A detailed understanding of the temporal and structural components of these interactions may be used to augment the host’s immune protection system. These components include the glycans and their receptors on both the host and the viral surface. It is anticipated that unravelling the interactions of the host’s glycans with viral receptors will allow for the development of practical diagnostic and therapeutic modalities. The SARS-CoV-2 virus utilizes its spike protein for attachment and internalization into host cells as a pivotal event required for viral replication. There is evidence that the first step of these events is the interaction of the N-terminal domain (NTD) of the spike protein with sialic acid-based receptors lining the respiratory tract. The aim of this Project is to identify key competitor glycans to the postulated SARS-CoV-2 virus glycan receptor that may also be useful for the development for both diagnostics and therapeutics.
Department
Program
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Recipient
Location
Ottawa|Ottawa, Ontario, Canada
Recipient Type
For-profit organization
Business Number
897184792
Type
Grant
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2022-03-31
Agreement Number
972122
Agreement Start Date
2021-05-10
Agreement Title
Synthesis and testing of glycan scaffolds (mono- and multi-valent forms) for evaluating glycan receptors of SARS-CoV-2
Agreement Title (French)
Synthèse et test des échafaudages de glycanes (formes monovalentes et multivalentes) pour l’évaluation des récepteurs de glycanes du virus du SRAS-CoV-2
Agreement Type
Grant
Agreement Value
$101,635.00
Amendment Number
0
Description
For pathogens such as the SARS-CoV-2 virus that are spread through inhalation, the cells of the lung are the first line of defense for the host. A detailed understanding of the temporal and structural components of these interactions may be used to augment the host’s immune protection system. These components include the glycans and their receptors on both the host and the viral surface. It is anticipated that unravelling the interactions of the host’s glycans with viral receptors will allow for the development of practical diagnostic and therapeutic modalities. The SARS-CoV-2 virus utilizes its spike protein for attachment and internalization into host cells as a pivotal event required for viral replication. There is evidence that the first step of these events is the interaction of the N-terminal domain (NTD) of the spike protein with sialic acid-based receptors lining the respiratory tract. The aim of this Project is to identify key competitor glycans to the postulated SARS-CoV-2 virus glycan receptor that may also be useful for the development for both diagnostics and therapeutics.
Description (French)
Pour les agents pathogènes tels que le virus du SRAS-CoV-2 qui se propagent par inhalation, les cellules du poumon constituent la première ligne de défense de l’hôte. Une compréhension détaillée des composants temporels et structurels de ces interactions peut être utilisée pour renforcer le système de protection immunitaire de l’hôte. Ces composants comprennent les glycanes et leurs récepteurs à la surface de l’hôte et du virus. La compréhension des mécanismes d’interaction entre les glycanes de l’hôte et les récepteurs viraux devrait permettre de mettre au point des modalités diagnostiques et thérapeutiques concrètes. Le virus du SRAS-CoV-2 utilise sa protéine de spicule pour s’attacher et s’internaliser dans les cellules de l’hôte, ce qui constitue un évènement déterminant nécessaire à la réplication virale. Il existe des preuves que la première étape de ces évènements est l’interaction du domaine N-terminal de la protéine de spicule avec les récepteurs à base d’acide sialique qui tapissent les voies respiratoires. L’objectif de ce projet est de recenser les principaux glycanes concurrents du récepteur des glycanes postulé du virus SRAS-CoV-2 qui pourraient également être utiles pour le développement de diagnostics et de thérapies.
Expected Results
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Expected Results (French)
À court terme, les résultats prévus seront des collaborations renforcées entre l'industrie, le milieu universitaire et le gouvernement pour soutenir l'excellence en recherche. À moyen terme, les résultats attendus seront le développement de nouvelles technologies potentiellement perturbatrices avec des collaborateurs. À long terme, trouver des solutions collaboratives aux défis des politiques publiques et créer des systèmes d'innovation plus solides.
Federal Riding
Ottawa–Vanier
Federal Riding (French)
Ottawa–Vanier
Federal Riding Number
35078
NAICS Code
541710 - R&D in the physical, engineering and life sciences
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Name (French)
Programme de collaboration en science, en technologie et en innovation - Initiatives de collaboration en R-D
Program Purpose
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
Program Purpose (French)
Collaborer à des programmes multipartites de recherche-développement dans le but de profiter de la synergie entre la recherche transformatrice à haut risque et à haut rendement et le potentiel de découvertes scientifiques et de percées technologiques révolutionnaires dans des secteurs d’intervention prioritaires.
Recipient Business Number
897184792
Recipient City
Ottawa|Ottawa
Recipient Country
CA
Recipient Legal Name
Sussex Research Laboratories Inc
Recipient Postal Code
K1A 0R6
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2021-2022-Q1-972122